Grants and Contributions:
Title:
An Innovative Liquid Oral Pediatric Formulation of MB-204 for Neurodevelopmental Disorders
Agreement Number:
1038358
Agreement Value:
$47,000.00
Agreement Date:
Jan 5, 2026 - Mar 30, 2026
Description:
MB-204 is a novel therapeutic candidate with the potential to treat pediatric neurodevelopmental disorders, including Autism, Rett syndrome, and Fragile X syndrome. Many of these patients experience swallowing difficulties or require feeding tubes, creating a need for child-friendly dosage forms. Through this project, Marvel will develop a liquid oral formulation of MB-204 suitable for syringe or tube dosage.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Calgary, Alberta, CA T2P 1G2
Reference Number:
172-2025-2026-Q4-1038358
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
793977505
Recipient Type:
For-profit organization
Recipient's Operating Name:
Marvel Biosciences
Recipient's Legal Name:
MARVEL BIOSCIENCES CORP.
Federal Riding Name:
Calgary Centre
Federal Riding Number:
48004
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
541710